TIGIT and melanoma: Simultaneous blocking of PD-L1 and TIGIT restored ex vivo effector T cell response in patients with advanced melanoma, and notably in chronic HIV infection, proposing TIGIT as a novel target for personalized therapy approach in PLHIV [17,18,19].